Targeting TREM2 on tumor-associated macrophages enhances immunotherapy

Binnewies et al.

Cell Reports 37, 109844 October 19, 2021 a 2021 Pionyr Immunotherapeutics.

Binnewies et al. show that TREM2- expressing tumor-associated macrophages (TAMs) are critical mediators of immune suppression in the tumor microenvironment (TME) and correlate with T cell exhaustion in human cancer. Effector-enhanced anti-TREM2 antibody treatment alters the abundance and phenotype of TAMs in the TME and sensitizes the response to anti-PD-1 therapy.